Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting.

Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Abstract Text:

Carla B C ,Leila B Moreira,Miguel Gus, Fuchs,Carla B C ,Leila B Moreira,Miguel Gus, Fuchs,Carla B C ,Leila B Moreira,Miguel Gus, Fuchs,

OBJECTIVES: Our primary objective was to determine the incidence of AEs of antihypertensive drugs in a cohort of outpatients attending a specialized clinic. The secondary objectives were to determine the incidence of AEs by classes of blood-pressure-lowering drugs used in monotherapy and to identify risk factors for the occurrence of AEs. METHODS: In a prospectively planned cohort study, patients attending a hypertension outpatient clinic were systematically interrogated about the occurrence of AEs of blood-pressure-lowering drugs. We compared the incidence of AEs by classes of drugs employed in monotherapy and identified risk factors for the occurrence of AEs in a logistic regression model. RESULTS: Participants were followed for 12.3 +/- 12.2 months. In total, 534 (35.4%) of 1,366 patients treated with blood pressure drugs complained of at least one AE during the follow-up, corresponding to an incidence of 31.3 AEs per 1,000 patients/month [95% confidence interval (CI) 28.6-33.9). The systolic blood pressure in the initial evaluation (P = 0.002) and use of two or more drugs (P < 0.001) were associated with higher incidence of AEs. The incidence of AEs was higher among patients treated with calcium channel blockers in monotherapy than in patients treated with diuretics (47.2 vs. 7.6%, P < 0.001). CONCLUSION: Adverse events of blood-pressure-lowering drugs are quite frequent in a clinical context, and may influence the adherence to treatment. Patients under treatment with diuretics in monotherapy have the lower incidence of AEs.

Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Publishing Authors By Initials

CB ,LB Moreira,M Gus,FD Fuchs,CB ,LB Moreira,M Gus,FD Fuchs,CB ,LB Moreira,M Gus,FD Fuchs,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of clinical pharmacology

VOLUME: 63

Page Numbers: 973-8

Journal Abbreviation: Eur. J. Clin. Pharmacol.

ISSN: 0031-6970

DAY: 11

MONTH: 08

YEAR: 2007

Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 1256165

Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting.

AFFILIATION: Schools of Pharmacy and Medicine, Universidade de Passo Fundo, Passo Fundo, Brazil.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Clin Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting Related Publications

• 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
• Acute myelopathy. Retrospective clinical, laboratory, MRI and outcome analysis of 49 cases.
• Adjuvant and neoadjuvant approaches in gastric cancer.
• Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting.
• Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
• Calcium-pterin suppresses mitogen-induced tryptophan degradation and neopterin production in peripheral blood mononuclear cells.
• Canonical notch signaling functions as a commitment switch in the epidermal lineage.
• Cardiac tamponade: a life-threatening complication of Still's disease.
• Catenins: keeping cells from getting their signals crossed.
• Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts.
• Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer.
• Contribution of the frontal eye field to gaze shifts in the head-unrestrained monkey: effects of microstimulation.
• CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
• Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
• Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
• Focal adhesion kinase modulates tension signaling to control actin and focal adhesion dynamics.
• GABAA but not GABAB receptors in the rostral anterior cingulate cortex selectively modulate pain-induced escape/avoidance behavior.
• Hormone replacement therapy and survival after colorectal cancer diagnosis.
• Identification of novel genes in genomic islands that contribute to Salmonella typhimurium replication in macrophages.
• Long-term aspirin use and mortality in women.
• Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling.
• Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP.
• Neurogenesis in the adult brain: is there an association with mental disorders?
• Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells.
• Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
• Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts.
• Ruthenium-catalyzed mild C-H oxyfunctionalization of cyclic steroidal ethers.
• Suicide attempt aborted by an implantable defibrillator.
• Tcf3 governs stem cell features and represses cell fate determination in skin.
• The relationship between basal level of anxiety and the affective response to inflammation.